We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E PHARMA, will be presenting at the Investment Summit Session of BIO Asia–Taiwan 2026 conference. Time: 16:15-17:20 Roadshow, Wednesday, July 15, 2026 Venue: Room 701AB, 7F, TaiNEX2 Dr. Chu will present the latest R&D progress across our pipeline, including the most recent clinical progress […]
Join our presentation at the BIO Asia-Taiwan 2026 Conference Read More »
T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review article introducing our core technology platform “Multi-Arm Linkers”, highlighting its innovative design and broad applications in novel drug development. JCCS is one of Taiwan’s longest-established SCI-indexed chemistry journals. It is published by the Chemical Society
Our Core Technology Platform Published in the Journal of the Chinese Chemical Society Read More »
T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the development of its novel therapeutic pipeline, expand its global strategic presence, and strengthen its capital structure. The company is also actively pursuing international partnership opportunities, with the goal of listing on the Taiwan Emerging Stock
Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more convenient sublingual delivery form! We are thrilled to announce the publication of our paper, entitled “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice”, has been published
Our Latest Research Published in International Journal of Pharmaceutics Read More »
We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the T-E Pharma, have been invited to participate in BIOLOGICS WORLD TAIWAN 2026, to be held in Taiwan, where they will deliver keynote presentations. BIOLOGICS WORLD TAIWAN is Taiwan’s premier annual biotherapeutics industry event, organized by the international
Join our presentation at the BIOLOGICS WORLD TAIWAN 2026 Read More »
“The development of TE-6168, the novel thrombolytic fusion protein” was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan. The CDE case number is 115IDX02001.
T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma. After achieving remarkable
In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview with Lifestyle Forum, Chairman Tse-Wen Chang highlighted the innovative drug design of TE-8214 and its potential breakthrough applications in clinical settings. Looking ahead to 2026, Immunwork will initiate the next phases of clinical trials for
Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), TE-8105, developed for the treatment of obesity. Conducted in Australia, the study demonstrated that TE-8105 is safe, well tolerated, and exhibits clear weight-loss potential, with only mild adverse
